A single oral dose of chlortenoxicam 4 mg, a new non-steroidal anti-inflammatory drug, significantly antagonized the diuretic and natriuretic actions of frusemide when compared with placebo in normal human volunteers. Indomethacin 50 mg significantly reduced the natriuretic, but not diuretic action of frusemide.
Introduction
The diuretic and natriuretic actions of frusemide and other loop and thiazide diuretics are antagonized by concurrent treatment with most, if not all, nonsteroidal anti-inflammatory drugs.'`Chlortenoxicam is a new non-steroidal anti-inflammatory drug of the oxicam group,5 and because it may be given to patients requiring treatment with frusemide it is important to know if it influences frusemide-induced diuresis and natriuresis.
Methods
Twelve healthy volunteers of either sex (6 females) aged 22-45 years were studied. The study was doubleblind, randomized and placebo controlled, using a three-way cross-over comparison of chlortenoxicam, indomethacin as a positive control and placebo.
The study was approved by the local ethics committee, every subject gave written consent to participate, and all completed the study.
Volunteers avoided alcoholic and caffeinecontaining drinks for 24 hours before and during each study day, moderated their intake of foods high in sodium and potassium for 3 days prior to each study day, and avoided medication containing aspirin for one week before each study day. Smoking was prohibited on the study days. The following oral treatments were given at 08.00 h after an overnight fast and a light breakfast on three separate occasions at least one week apart: chlortenoxicam 4 mg, indomethacin 50 mg and matched placebo. One hour after each treatment, frusemide 20 mg orally was given. All treatments were taken with 100 ml water. Following administration of frusemide, 100 ml water was given hourly for 6 hours.
Volunteers emptied their bladders before receiving the test treatments and hourly total urine collections were made up to 6 h after the dose of frusemide. Urine volumes were recorded and 10 ml aliquots stored at -200 C until analysis.
Urinary sodium and potassium concentrations were analysed by automated flame photometry (IL 943, Instrument Laboratory (UK) Ltd). The instrument was calibrated using a standard containing 100 mmol/l of both sodium and potassium. The calibration was checked and the instrument recalibrated automatically every 16 samples.
An independent running quality sample was analysed every 7 test samples. Coefficients of variation were 0.1 for both sodium and potassium estimations.
The urine volume and total excretion per hour of sodium and potassium were analysed using multiple linear regression analysis with treatments, time of measurements and subjects included as independent variables, using the dummy variable technique. Chlortenoxicam and indomethacin were compared with the placebo.
Results
Mean values for urinary volume, sodium and potassium excretion associated with the three treatments are shown in Figure 1 and the results of the statistical analysis in Table I 
Discussion
Non-steroidal anti-inflammatory drugs (NSAID) influence renal function in at least two ways. Firstly, 
